Sponsored Symposia Programme
Sponsored Symposia Programme
Please click on the below accordion to read the content of each section.
14:30 – 15:30
| Shionogi Sponsored Symposium: Ospemifene: Can satisfaction and adherence impact clinical outcome of VVA treatment? The management of Vulvo-Vaginal Atrophy (VVA) in menopausal women caused by physiological decline of oestrogen levels continues to evolve as new evidence and treatment strategies become available. In this symposium we aim to underline, through the exchanging of clinical experiences with ospemifene, the importance of patient’s satisfaction and adherence to treatment to obtain better therapeutic outputs. We also aim to share the emerging real-world evidence on the use of ospemifene to treat VVA as first-line treatment in menopausal women. Chair: Santiago Palacios (Madrid, Spain) |
14:30 – 14:40 | Ospemifene: the only first-line oral treatment for women with moderate to severe VVA Speaker: Santiago Palacios (Madrid, Spain) |
14:40 – 14:55 | Spanish real-world evidence on women satisfaction with VVA treatments in clinical practice: the CRETA study results Speaker: Carmen Pingarron (Spain) |
14:55 – 15:05 | Italian real-world assessment of the use of oral and local treatment for moderate and severe VVA: the PEONY study Speaker: Rossella Nappi (Italy) |
15:05 – 15:25 | Treating VVA in post-menopausal women with comorbidities in clinical practice Speakers: Santiago Palacios (Madrid, Spain) Rossella Nappi (Italy) Silvia Maffei (Pisa, Italy) Tommaso Simoncini (Italy) |
15:25 – 15:30 | Closing remarks Speaker: Santiago Palacios (Madrid, Spain) |
15:45 – 16:45
| Novo Nordisk Sponsored Symposium: Obesity in Menopause: A paramount call to action for women´s health |
The symposium will begin by introducing how obesity affects women throughout their life, with a deep focus on the physiopathology of obesity in menopause and perimenopause and the clinical management of obesity and overweight in menopause with present and future recommendations.
Chair: Santiago Palacios Speakers: Santiago Mayo (Medical Manager, Novo Nordisk Spain) Rossella Nappi (Italy) Peter Chedraui (Ecuador) |
12:30 – 14:00
| MYLAN ITALIA S.R.L. (Viatris) Sponsored Symposium: Doublepause: from pause to play |
12:30 – 12:35 | Introduction Speaker: Emmanuele A. Jannini |
12:35 – 12:50 | Doublepause: A New Paradigm in Treating Sexual Dysfunction Speaker: Emmanuele A. Jannini |
12:50 – 13:05 | Female sex hormones and its role in desire and arousal Speaker: Rossella Nappi (Italy) |
13:05 – 13:20 | Approach towards the couple from the gynecologist’s perspective Speaker: Katrin Schaudig (Germany) |
13:20 – 13:35 | Couple-thinking: A new way of approaching sexual problems Speaker: Anna Maria Giraldi |
13:35 – 13:55 | Fireside discussion and Q&A on taking a multi-disciplinary approach to Doublepause Speakers: All |
13:55 – 14:00 | Closing remarks Speaker: Emmanuele A. Jannini, Rossella Nappi (Italy) |
12:30 – 14:00
| Theramex Sponsored Symposium: Get ahead of the change – current menopause treatment navigation Chair: Rossella Nappi (Italy) |
12:30 – 12:40 | From contraception through transition period to adopting an individualized approach for women in the management and treatment of menopause Speaker: Rossella Nappi (Italy) |
12:40 – 13:10 | Could oral body-identical estradiol/micronized progesterone be the treatment option for all postmenopausal women? Speaker: Petra Stute (Switzerland) |
13:10 – 13:30 | When transdermal treatment options are the right choice? Speaker: Paula Briggs (United Kingdom) |
13:30 – 13:55 | When non-hormonal treatment is a choice: Menopause management with the natural selective estrogen receptor modulator DT56a Speaker: Amos Ber (Israel) |
13:55 – 14:00 | Session closing |
12:30 – 13:00
| Fotona Sponsored Symposium: Vaginal erbium laser (VEL) for women in menopause |
1. VEL for improvement of GSM symptoms and sexual function 2. VEL for improvement of SUI 3. Laser treatment using intraurethral probe – What are the benefits? |
